Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer

Zhao,Henan; Liu,Sha; Wang,Guang; Wu,Xian; Ding,Yanfang; Guo,Gordon; Jiang,Jiyong; Cui,Shiying

doi:10.3892/or.2014.3640

February-2015 Volume 33 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

February-2015 Volume 33 Issue 2

Full Size Image

Article

Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer

Authors:
- Henan Zhao
- Sha Liu
- Guang Wang
- Xian Wu
- Yanfang Ding
- Gordon Guo
- Jiyong Jiang
- Shiying Cui
View Affiliations / Copyright

Affiliations: Dalian Medical University, Dalian, Liaoning 116044, P.R. China, Department of Radiation Oncology, University of Manitoba, Winnipeg, MB R37 2N2, Canada, Obstetrics and Gynecology Hospital, Dalian, Liaoning 116003, P.R. China
Pages: 591-598
|
Published online on: December 2, 2014

https://doi.org/10.3892/or.2014.3640
Expand metrics +

Abstract

MicroRNAs (miRNAs) are involved in regulating the response of cancer cells to various therapeutic interventions, yet their involvement in the chemoresistance of human epithelial ovarian cancer is not fully understood. We found that miR-136 was significantly downregulated in specimens from patients with chemoresistant epithelial ovarian cancer. In the present study, we aimed to clarify the role of miR-136 in regulating the chemoresistance of ovarian cancer. Thirty-four tumor bank specimens and 2 well-established human ovarian cancer cell lines, C13 and OV2008, were used. We found that miR-136 expression was significantly reduced in primary platinum-resistant patients and the ovarian cancer OVC cell line. Enforced expression of miR-136 decreased the chemoresistance to cisplatin in OVC cells through inhibition of cell survival. In addition, we found no association between miR-136 and migration or invasion potential in the ovarian cancer cell lines. However, in the platinum-resistant C13 cell line, the overexpression of miR-136 markedly promoted an apoptotic response to cisplatin. Furthermore, the levels of adducts corrected with their extent of DNA damage/repair, in terms of the percentage of DNA in comet tails, tail length, tail moment (TM), and olive tail moment (OTM), revealed that miR-136 is essential for the repair of cisplatin-induced DNA damage. Our findings suggest that miR-136 may function as an anti-oncogene and deficiency of miR-136 expression in ovarian cancer can induce chemoresistance at least in part by downregulating apoptosis and promoting the repair of cisplatin-induced DNA damage. Thus, miR-136 may provide a biomarker for predicting the chemosensitivity to cisplatin in patients with epithelial ovarian cancer.

View Figures

View References

1	Zhao H, Ding Y, Tie B, et al: miRNA expression pattern associated with prognosis in elderly patients with advanced OPSC and OCC. Int J Oncol. 43:839–849. 2013.PubMed/NCBI
2	Matei DE and Nephew KP: Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol Oncol. 116:195–201. 2010. View Article : Google Scholar :
3	Yu X, Zhang X, Bi T, et al: MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma. Tumour Biol. 34:3501–3508. 2013. View Article : Google Scholar : PubMed/NCBI
4	Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI
5	Chen Y, Ke G, Han D, Liang S, Yang G and Wu X: MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD. Exp Cell Res. 320:12–20. 2014. View Article : Google Scholar
6	Iorio MV and Croce CM: microRNA involvement in human cancer. Carcinogenesis. 33:1126–1133. 2012. View Article : Google Scholar : PubMed/NCBI
7	Meng F, Henson R, Lang M, et al: Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 130:2113–2129. 2006. View Article : Google Scholar : PubMed/NCBI
8	Yang H, Kong W, He L, et al: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
9	Passetti F, Ferreira CG and Costa FF: The impact of microRNAs and alternative splicing in pharmacogenomics. Pharmacogenomics J. 9:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
10	Ratner ES, Keane FK, Lindner R, et al: A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene. 31:4559–4566. 2012. View Article : Google Scholar :
11	Rubatt JM, Darcy KM, Tian C, et al: Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study. Gynecol Oncol. 125:421–426. 2012. View Article : Google Scholar : PubMed/NCBI
12	Rustin GJ, Nelstrop AE, Bentzen SM, Piccart MJ and Bertelsen K: Use of tumour markers in monitoring the course of ovarian cancer. Ann Oncol. 10:21–27. 1999. View Article : Google Scholar : PubMed/NCBI
13	Rustin GJ, Nelstrop AE, McClean P, et al: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol. 14:1545–1551. 1996.PubMed/NCBI
14	Pérez C, Díaz-García CV, Agudo-López A, et al: Evaluation of novel trans-sulfonamide platinum complexes against tumor cell lines. Eur J Med Chem. 76:360–368. 2014. View Article : Google Scholar : PubMed/NCBI
15	Gyori BM, Venkatachalam G, Thiagarajan PS, Hsu D and Clement MV: OpenComet: An automated tool for comet assay image analysis. Redox Biol. 2:457–465. 2014. View Article : Google Scholar : PubMed/NCBI
16	van Huis-Tanja LH, Kweekel DM, Lu X, Franken K, et al: Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin. Mutat Res Fundam Mol Mech Mutagen. 759:37–44. 2014. View Article : Google Scholar
17	Giovannetti E, Erozenci A, Smit J, Danesi R and Peters GJ: Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol. 81:103–122. 2012. View Article : Google Scholar
18	Li Z, Hu S, Wang J, Cai J, Xiao L, Yu L and Wang Z: MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol. 119:125–130. 2010. View Article : Google Scholar : PubMed/NCBI
19	Shen S, Yue H, Li Y, Qin J, Li K, Liu Y and Wang J: Upregulation of miR-136 in human non-small cell lung cancer cells promotes Erk1/2 activation by targeting PPP2R2A. Tumour Biol. 35:631–640. 2014. View Article : Google Scholar
20	Kweekel DM, Gelderblom H and Guchelaar HJ: Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev. 31:90–105. 2005. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles